ADVENTRX PHARMACEUTICALS INC Form 8-K November 02, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

ADVENTRX Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

001-32157

(Commission

File Number)

Delaware

(State or other jurisdiction of incorporation)

6725 Mesa Ridge Road, Suite 100, San Diego, California

(Address of principal executive offices)

Registrant s telephone number, including area code:

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

84-1318182

(I.R.S. Employer Identification No.)

92121

(Zip Code)

858-552-0866

November 2, 2007

Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 8-K

<u>Top of the Form</u> Item 8.01 Other Events.

On November 2, 2007, ADVENTRX Pharmaceuticals, Inc. issued a press release providing an update on its ANX-510, or CoFactor®, program. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Index to Exhibits filed with this report.

Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

November 2, 2007

By: /s/ Evan M. Levine

Name: Evan M. Levine Title: Chief Executive Officer

Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description

99.1

Press release, dated November 2, 2007